Completed PHASE2 INTERVENTIONAL NCT00269672

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects

A Randomized, Open Label, Controlled Phase II Study to Evaluate Safety, Tolerability and Immunogenicity After Two Different 13-Valent Pneumococcal Conjugate Vaccine Formulations in Elderly Subjects Aged 65 Years and Older Who Are Naive to Previous 23vPS Immunization

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Conditions Vaccines, Pneumococcal Conjugate Vaccine

Interventions 13-valent Pneumococcal Conjugate Vaccine

Updated 5 times since 2017 Last updated: Aug 4, 2010 Started: Sep 30, 2005 Primary completion: Feb 28, 2007 Completion: Feb 28, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00269672, this PHASE2 trial focuses on Vaccines, Pneumococcal Conjugate Vaccine and remains completed. Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Wyeth is now a wholly owned subsidiary of Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.